Decipher® Transcriptomic Analysis in Non-American Prostate Cancer Cohort
Dr. Daniel Keizman and colleagues have demonstrated that the Decipher® genomic classifier significantly reclassifies NCCN risk groups in early prostate cancer patients. By analyzing transcriptomic signatures in non-American cohorts, the ... Read More